BW-50218 Injection

DRUG2 trials

Sponsors

Shanghai Argo Biopharmaceutical Co., Ltd.

Conditions

Healthy Participants Study

Phase 1

Study of BW-50218 in Healthy Participants

Active, not recruitingNCT07401472

Shanghai Argo Biopharmaceutical Co., Ltd.Healthy Participants Study

Start: 2026-03-12End: 2027-06-30Target: 60Updated: 2026-09-03

A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants

Active, not recruitingNCT07577479

Shanghai Argo Biopharmaceutical Co., Ltd.Healthy Participants Study

Start: 2026-05-18End: 2028-04-30Target: 24Updated: 2026-06-24